Association of Clinical Trials Organizations (ACTO) Newsletter No. 7
Moscow 2013
The Association of Clinical Trials Organizations (ACTO) presented newsletter No. 7 with results from the first half of 2013 detailing the state of clinical trials in Russia.
During the first half of 2013, the Russian Ministry of Health issued 404 approvals for conducting clinical trials, down 10% from the same time last year. The number of international trials is also down 14.1% from last year, as is the number of bioequivalence studies, which is down 20.7%.
You can read the full report, including analysis of these numbers and thoughts on possible causes, (PDF) here.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
